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Abstract
Pyrrole-imidazole (Py-Im) polyamides are high affinity DNA-binding small molecules that
can inhibit protein-DNA interactions. In VCaP cells, a human prostate cancer cell line over-
expressing both AR and the TMPRSS2-ERG gene fusion, an androgen response element
(ARE)-targeted Py-Im polyamide significantly downregulates AR driven gene expression.
Polyamide exposure to VCaP cells reduced proliferation without causing DNA damage. Py-
Im polyamide treatment also reduced tumor growth in a VCaP mouse xenograft model. In
addition to the effects on AR regulated transcription, RNA-seq analysis revealed inhibition
of topoisomerase-DNA binding as a potential mechanism that contributes to the antitumor
effects of polyamides in cell culture and in xenografts. These studies support the therapeutic
potential of Py-Im polyamides to target multiple aspects of transcriptional regulation in pros-
tate cancers without genotoxic stress.
Introduction
Pyrrole imidazole (Py-Im) polyamides are non-covalent, sequence specific DNA binders that can
alter DNA architecture [1, 2]. Upon high affinity binding to the DNAminor groove, the mole-
cules cause a 4 angstrom widening of the minor groove walls and a corresponding compression
of the opposing major groove [3, 4]. Despite the relatively large molecular weight of Py-Im poly-
amides, these molecules are cell permeable and localize to the cell nucleus to affect endogenous
gene expression [5–10]. Due to their modular sequence specificity, Py-Im polyamides can be syn-
thesized to target DNA sequences of similar size to a protein-DNA interaction site and therefore
used to antagonize gene expression driven by specific transcription factors [7, 9–13]. One such
transcription factor that has been studied previously is the androgen receptor (AR) [9].
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The AR is a dihydrotestosterone (DHT) inducible nuclear hormone receptor whose transcrip-
tional program has been implicated in the progression of prostate cancer [14–16]. Upon ligand
induction, AR will homodimerize, translocate to the nucleus and bind to conserved sequences
known as the androgen response element (ARE) to regulate transcription [17]. Each monomeric
unit binds to a half site of the sequence 5’-TGTTCT-3’ [18]. Polyamide 1 (Fig 1) was designed to
target the sequence 5’-WGWWCW-3’ (W = A/T), found in a subset of ARE half-sites, and has
been shown to prevent AR binding at select AREs and attenuate AR signaling [9].
In addition to antagonizing AR signaling, polyamide 1 is also cytotoxic towards prostate
cancer cells [19]. Experiments in mice have shown that polyamide 1 is bioavailable via several
routes of administration, with a serum half-life of 5.2 hours [20, 21]. In xenograft experiments,
polyamide 1 has been shown to be active towards LNCaP xenografts at doses of 1 mg/kg [19].
LNCaP, however, expresses a mutated androgen receptor, and as a result, may not be represen-
tative of the majority of human disease [22]. It would therefore be useful to evaluate the efficacy
of 1 against other forms of prostate cancer.
The VCaP human prostate cancer cell line expresses wild type AR and contains the
TMPRSS2-ERG fusion [23]. Gene fusions between the TMPRSS2 5’-untranslated region and
the ERG oncogene are found in approximately half of prostate cancer cases [24]. The fusion
allows the AR regulated TMPRSS2 promoter to drive the expression of ERG, and overexpres-
sion of ERG in patients has been linked with higher incidences of metastasis and poor disease
prognosis [25]. In cell culture, ERG overexpression in immortalized prostate RPWE epithelial
cells and in primary prostate epithelial cells (PrEC) has been shown to increase cellular inva-
siveness [26]. Due to these characteristics, the VCaP cell line presents an ideal model for the
study of Py-Im polyamide activity towards this common subtype of prostate cancer. In this
study, we evaluated the activity of the ARE targeted polyamide 1 in VCaP cells.
Materials and Methods
Synthesis and quantitation of Py-Im polyamide 1
Chemicals were obtained from Sigma Aldrich or Fisher Scientific unless otherwise noted. Syn-
thesis was performed using previously reported procedures as indicated [7, 27]. Briefly, poly-
amides were synthesized by microwave-assisted solid phase synthesis on Kaiser oxime resin
(Nova Biochem) [27] and then cleaved from the resin with neat 3,3’-diamino-N-methyldipro-
pylamine. The triamine-conjugated polyamides were purified by reverse phase HPLC and sub-
sequently modified at the C-terminus with isophthalic acid (IPA) or fluorescein-
5-isothiocyanate (FITC isomer I, Invitrogen) [7]. The amine substituents of the γ-aminobutyric
acid (GABA) turn units of the polyamides were deprotected using neat trifluoroacetic acid [28,
29]. The final polyamide was purified by reverse phase HPLC, lyophilized to dryness, and
stored at -20°C. The identity and purity of the final compounds were confirmed by matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) spectrometry and analytical
HPLC. Chemical structures are represented in Fig 1 and S1 Fig Mass spectrometry characteri-
zation data are represented in S2 Fig.
Py-Im polyamides were dissolved in sterile dimethylsulfoxide (DMSO, ATCC) and quantitated
by UV spectroscopy in either 4:1 0.1% TFA (aqueous):acetonitrile (ε(310nm) = 69,500M-1cm-1) or
9:1 water:DMSO (ε(310nm) = 107,100M-1cm-1) as dictated by solubility. Polyamides were added
to cell culture solutions at 1000x concentration to give 0.1% DMSO solutions.
Cell culture
The VCaP cell line was obtained from the laboratories of Dr. Kenneth J. Pienta and Dr. Arul
M. Chinnaiyan at the University of Michigan Department of Pathology, where the cell line was
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derived [30]. VCaP cells were received at passage 19 and cultured in Dulbecco’s modified eagle
medium (DMEM, Gibco 10313–039) with 4 mM glutamine (Invitrogen) and fetal bovine
serum (FBS, Omega Scientific) on Corning CellBind flasks. All experiments were performed
below passage 30.
Cellular uptake studies
For visualization of uptake using FITC-analog polyamides, VCaP cells were plated in 35-mm
optical dishes (MatTek) at 7.5×104 cells per dish and allowed to adhere for 48 h. Media was
then changed and cells were treated with 0.1% DMSO with polyamide for 24 or 48 h. Cells
were imaged at the Caltech Beckman Imaging Center using a Zeiss LSM 5 Exciter inverted
laser scanning microscope equipped with a 63x oil immersion lens as previously described [5].
WST-1 proliferation assay
VCaP cells were plated at 2x104 per well in 96-well plates coated with poly-L-lysine (BD Bio-
Coat). After 24 h, an additional volume of medium containing vehicle or polyamide was added
to each well. All medium was removed following polyamide incubation at the indicated time
points and replaced with one volume of WST-1 reagent (Roche) in medium according to man-
ufacturer protocol. After 4 h of incubation at 37°C, the absorbance was measured on a FlexSta-
tion3 plate reader (Molecule Devices). The value of A(450 nm)-A(630 nm) of treated cells was
referenced to vehicle treated cells. Non-linear regression analysis (Prism software, Graphpad)
was performed to determine IC50 values.
Fig 1. Chemical structure of a Py-Im polyamide (1) designed to target the DNA sequence 50-WGWWCW-30. A ball and stick notation is used to
represent binding to the target DNA sequence. Pairing of an imidazole heterocycle (black circle) with a pyrrole heterocycle (white circle) allows G•C
recognition, and the pairing of two pyrrole heterocycles recognizes A•T or T•A base pairs.
doi:10.1371/journal.pone.0143161.g001
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Gene expression analysis by quantitative RT-PCR (qPCR)
For DHT induction experiments, VCaP cells were plated in 6-well plates coated with poly-L-
lysine (BD BioCoat) in charcoal-treated FBS containing media at a density of 31k/cm2 (3x105
cells per well). The cells were allowed to adhere for 24 h and then dosed with 0.1% DMSO with
or without polyamide 1 for 72 h followed by the addition of 0.01% ethanol in PBS with or with-
out DHT (1 nM final concentration). Cells were harvested after additional 24 h incubation.
Cells treated with etoposide and camptothecin (Sigma) were co-treated with DHT (1 nM) and
harvested after a 16 h incubation. For native expression experiments, VCaP cells were plated as
above but using standard FBS media and harvested after 72 h of treatment. For all experiments,
the mRNA was extracted using the QIAGEN1 RNeasy mini kit following the standard purifi-
cation protocol. Samples were submitted to DNAse treatment using the TURBO DNA-free™
Kit (Ambion), and the mRNA was reverse-transcribed by using the Transcriptor First Strand
cDNA Synthesis Kit (Roche). Quantitative PCR was performed by using the FastStart Univer-
sal SYBR Green Master (Rox) (Roche) on an ABI 7300 Real Time PCR System. Gene expres-
sion was normalized against GUSB. Primers used are referenced in S3 Fig.
Immunoblot of ERG protein levels
For assessment of ERG and beta-actin protein levels, 3x106 VCaP cells were plated in 10 cm
diameter dishes with charcoal-treated FBS containing media for 24 h before treatment with
0.1% DMSO vehicle with or without polyamide 1 for an additional 72 h. Ethanol (0.01%) in
PBS with or without DHT (1 nM final concentration) was then added. After 24 h incubation,
cells were lysed in TBS-Tx buffer (50 mM Tris-HCl pH 7.4, 150 mMNaCl, 1 mM EDTA, 1%
Triton X100) containing fresh 1 mM phenylmethanesulfonylfluoride (PMSF) and protease
inhibitors (Roche). The samples were quantified by Bradford assay, denatured by boiling in
Laemmli buffer, and total protein was separated by SDS-PAGE. After transfer to the polyvinyl
difluoride (PVDF) membrane (Bio-Rad) and blocking with Odyssey Blocking Buffer
(LI-COR), primary antibodies were incubated overnight at 4°C. Rabbit monoclonal anti-ERG
antibody (Epitomics 2805–1) and rabbit polyclonal anti-actin antibody (Sigma A2066) were
used. Goat anti-rabbit near-IR conjugated secondary antibody (LI-COR) was added and the
bands were visualized on an Odyssey infrared imager (LI-COR). The experiment was con-
ducted in duplicate and the data are representative of both trials.
Single cell electrophoresis (COMET) assay
VCaP cells (3x106 cells) were plated in 10 cm cell culture dishes and allowed to adhere for 24 h
before addition of DMSO vehicle or polyamide stock in DMSO. After 72 h incubation, cells
were washed with warm PBS (37°C), gently scraped, and counted. Samples were centrifuged,
resuspended at 1x105 cells/mL, and treated according to manufacturer protocol (Trevigen) for
neutral electrophoresis. Slides were stained with SybrGreen (Trevigen) and imaged at the Cal-
tech Beckman Imaging Center using a Zeiss LSM 5 Pascal inverted laser scanning microscope
equipped with a 5x air objective lens. Overlayed fluorescence and bright field images were
obtained using standard filter sets for fluorescein. Images were analyzed using Comet IV soft-
ware (Perceptive Instruments Ltd) with 200–600 comets measured per sample. A random sam-
pling of 200 comets per condition was used for two-way analysis of variance (ANOVA)
analysis (Prism software, GraphPad) of three biological replicates.
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Xenograft assays
Male severe combined immunodeficiency (SCID) mice (4–6 weeks old) were obtained from a
breeding colony maintained by the University of Michigan. Tumors were induced by subcuta-
neous injection of 1x106 VCaP cells (10 mice per dose group) in 200 μL of Matrigel (BD Biosci-
ences, Inc., San Jose, CA) above the right flank. Tumor growth was monitored by caliper
measurement until the tumor size reached 100 mm3 using the formula 0.56 x L xW2. Groups
were randomized and all mice were treated subcutaneously with control (DMSO) or with poly-
amide 1 as reported (3 times per week, 10 total injections). Tumor growth was followed weekly
by caliper measurements. Animal husbandry and daily care and medical supervision was pro-
vided by the staff of the Unit for Laboratory Animal Medicine (ULAM) under the guidance of
supervisors who are certified as Animal Technologists by the American Association for Labo-
ratory Animal Science (AALAS) at the University of Michigan. Animals were monitored twice
daily by both the research team and the veterinary staff. Health was monitored by weight
(twice weekly), food and water intake, and general assessment of animal activity, panting, and
fur condition. The experiments were performed in accordance with the guidelines on the care
and use of animals set by the University Committee for the Use and Care of Animals
(UCUCA) of the University of Michigan, and all procedures in this study were specifically
approved by the UCUCA (Protocol Number 3848). In all cases, appropriate measures were
taken to minimize discomfort to animals. All injections or surgical procedures were performed
using sterile technique with efforts made to minimize trauma to the animals. When necessary,
animals were anesthetized with a mixture of 1.75% isofluorane/air. Following injections ani-
mals were closely monitored and any that appeared moribund were immediately euthanized
by administration of anesthesia, followed by inhalation of carbon dioxide until breathing
ceased. Death was then ensured through cervical dislocation.
RNA-seq analysis
VCaP cells (1x106 cells) were plated in 20 cm cell culture dishes and allowed to adhere for 72 h
in DMEM containing 10% FBS and 4 mM glutamine. Polyamide 1 or 0.1% DMSO vehicle were
then added in fresh media and allowed to incubate for 96 h. Total RNA was collected by trizol
extraction. Library building and sequencing were performed at the Caltech Millard and Muriel
Jacobs Genetics and Genomics Laboratory. Sequenced reads were mapped against the human
genome (hg19) with Tophat2 using Ensembl GRCh37 gene annotations [31]. Exon alignment
was performed with htseq-count and differential expression was determined with DESeq2 [32,
33]. Genes with padj< 0.05 and |log2(fold change)| 1 were submitted for connectivity map
analysis online at http://lincscloud.org.
Topoisomerase inhibition assay
Topoisomerase inhibition kits were purchased from Topogen (Port Orange, FL). For Top2
relaxation assays, 540 ng Top2α-p170 fragment (16 units) was added to 250 ng supercoiled
pHOT1 DNA in assay buffer (0.05 M Tris-HCl (pH 8), 0.15 M NaCl, 10 mMMgCl2, 0.5 mM
dithiothreitol) plus 2 mM ATP with or without test compounds in a total volume of 20 μL. The
DMSO concentration was standardized to 1% for all samples except the no-DMSO solvent
controls. Reactions were incubated at 37°C for 30 min and then quenched with 2 μL 10%
sodium dodecyl sulfate solution. Samples were then extracted with chloroform: isoamyl alcohol
24:1, mixed with 2 μL 10x glycerol loading buffer and loaded onto 1% agarose gels in tris-acetic
acid-EDTA (TAE) buffer with or without 0.5 μg/mL ethidium bromide (EtBr). Gels run with-
out EtBr were post-stained with SYBR-Gold (Invitrogen).
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For Top1 assays, 0.5 μL Top1 (5 units) was added to 250 ng supercoiled pHOT1 DNA in
assay buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA) plus 2 μL reaction buffer (10 mM Tris-
HCl (pH 7.9), 1 mM EDTA, 0.15 M NaCl, 0.1% BSA, 0.1 mM spermidine, 5% glycerol) with or
without test compounds in a total volume of 20 μL. The DMSO concentration was again stan-
dardized to 1% for all samples except the no-DMSO solvent controls. Reactions were incubated
at 37°C for 30 min and then quenched with 4 μL stop buffer (0.125% bromphenol blue, 25%
glycerol, 5% Sarkosyl). Samples were then loaded onto 1% agarose gels in tris-acetic acid-
EDTA (TAE) buffer with or without 0.5 μg/mL ethidium bromide (EtBr). Gels run without
EtBr were post-stained with SYBR-Gold.
Results
Nuclear uptake and cytotoxicity of Py-Im polyamide
To test the nuclear uptake potential of polyamide 1, a FITC-labeled derivative was prepared
(1-FITC) and incubated with VCaP cells prior to imaging by confocal microscopy (S1 Fig).
Polyamide 1-FITC signal was observed in the nucleus and also showed significant membrane
binding. The overall level of uptake in VCaP cells was found to be qualitatively less than that in
LNCaP cells [21]. Next, polyamide 1 was evaluated for antiproliferation effects in VCaP cells
using the WST-1 assay under conditions similar to the gene expression experiment. After a
96 h incubation with polyamide, an IC50 value of 6.5 ± 0.3 μMwas determined for polyamide
1 (Fig 2A). At 72 h, the IC50 value for polyamide 1 in VCaP cells was found to be over 30 μM
(data not shown). For comparison, polyamide 1 has been found to have an IC50 of 7 ± 3 μM
after 72 h incubation in LNCaP cells [19].
Reduction of DNA damage in VCaP cells upon treatment with Py-Im
polyamide
The effect of polyamide 1 on the high level of extant DNA damage in VCaP cells was also
investigated. After incubation with polyamide, VCaP cells were submitted to the neutral
Comet assay, which allows visualization of double-strand breaks through single cell electropho-
resis (Fig 2B). The percentage of DNA in the “tail” of the comets was then compared using
two-way ANOVA statistical analysis (S4 Fig). A significant reduction in DNA damage
(p< 0.001) was observed with polyamide 1 over the vehicle control.
ARE-targeted Py-Im polyamide downregulates AR-driven
TMPRSS2-ERG expression
Next the effect of polyamide 1 on AR signaling in ERG-positive cells was examined. Dosage
concentrations were chosen based on previous reports of polyamide gene expression effects in
LNCaP [28, 34]. In VCaP cells, polyamide 1 was found to reduce the DHT-induced expression
of the TMPRSS2-ERG fusion as well as other AR target genes, including PSA and FKBP5 (Fig
2C). Corresponding decreased expression of ERG protein was confirmed by Western blot (Fig
2D). In the non-induced state, polyamide 1 was also found to reduce expression of several ERG
influenced genes, including PLAT andMYC (S5 Fig).
Diminished growth in VCaP xenografts upon polyamide treatment
We next moved from cell culture studies to investigations of polyamide 1 in a VCaP mouse
xenograft tumor model. Xenograft experiments were conducted in male SCID mice bearing
subcutaneous VCaP cell xenografts. Treatments were started after tumor sizes in each group of
mice reached ~100 mm3 and were administered three times per week through subcutaneous
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injection in DMSO vehicle for three weeks for a total of 10 injections. Dose-dependent retarda-
tion of tumor growth was observed in mice treated with polyamide 1 (Fig 3). After 5 weeks of
monitoring, tumors treated with vehicle grew to approximately 6-fold the initial volume of that
group while tumors treated with polyamide 1 at 5.0 mg/kg grew to approximately 1.6-fold the
initial volume of that cohort.
Genome wide expression analysis
RNA-seq analysis was performed after 96 hours of polyamide treatment in order to assess gene
expression changes after prolonged exposure and to identify potential mechanisms of polyam-
ide induced toxicity. Differential expression analysis using DESeq2 showed that of the genes
Fig 2. Cell culture characterization of polyamide 1 in VCaP cells. (A) Cytotoxicity of polyamide 1 in VCaP cells after 96 h incubation. (B) Quantification of
200 neutral comets from VCaP cells treated with 0.1% DMSO (vehicle) or 10 μM polyamide 1 for 72 h. Statistical significance was determined using two-way
ANOVA analysis (Prism) where *** = p < 0.001 relative to vehicle. Boxes are bounded by the upper and lower quartile, while whiskers represent the 1st and
99th percentile. (C) Effect of 10 μM polyamide 1 on select androgen receptor regulated genes in VCaP cells under 1 nM DHT induction. (D) Change in ERG
protein caused by 0.1% DMSO vehicle, 1 nM DHT alone, and cotreatment of 10 μM polyamide 1 with 1 nM DHT.
doi:10.1371/journal.pone.0143161.g002
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with padj< 0.05 and |log2(fold change)| 1, 342 were upregulated and 399 were downregulated
upon polyamide treatment (Fig 4A). Connectivity map analysis of these genes returned several
compounds known to be topoisomerase inhibitors (Fig 4B), suggesting that the polyamide may
also be interfering with topoisomerase activity. Analysis of a previously published genome wide
data set from LNCaP cells treated with polyamide 1 shows similar results (S6 Fig)[9].
Inhibition of topoisomerases 1 and 2
Topoisomerase inhibitors have been shown to attenuate AR signaling in multiple cell lines [35,
36]. Similar results are also seen in VCaP cells, where treatment with etoposide and camptothe-
cin is able to reduce DHT induced expression of select AR regulated genes (S7 Fig). Based on
the Connectivity map results, we examined the inhibitory effects of polyamide 1 against topo-
isomerase 1 and 2 in vitro. Topoisomerase 1 (Topo1) functions by relieving DNA supercoils
generated by transcription and replication and is a therapeutic target in cancer [37]. To deter-
mine if polyamide 1 inhibits Topo1 mediated DNA cleavage, we titrated polyamide 1 with
supercoiled pHOT1 plasmid and measured conversion to open circular plasmid or relaxation
upon addition of purified Topo1. A reduction in DNA relaxation indicates polyamide 1 was
able to attenuate Topo1 mediated cleavage of DNA (Fig 5A). To differentiate between open cir-
cular and relaxed DNA, samples were also run on an EtBr gel. Unlike camptothecin (CMT),
which traps the Topo1 cleavage complex and generates nicked open circular DNA, treatment
with polyamide 1 did not prevent DNA re-ligation. Topoisomerase II cleaves double stranded
DNA in an ATP dependent manner and is essential for strand separation of tangled daughter
Fig 3. VCaP xenografts treated with polyamide 1 three times per week showed a dose dependent reduction in tumor growth. Tumor volume was
determined by caliper measurements. Errors are SEM. * = p < 0.01, ** = p < 0.0005, *** = p < 0.0001.
doi:10.1371/journal.pone.0143161.g003
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chromosomes during replication. Like Topo1, Topo2 is targeted in cancer therapy [38]. Similar
to results seen for Topo1, polyamide 1 was able to inhibit Topo2 cleavage of supercoiled
pHOT1 plasmid in a concentration dependent manner (Fig 5B). Furthermore, samples were
run with EtBr to allow unambiguous identification of linearized DNA, which allowed the iden-
tification of Topo2 cleavage complex (Topo2cc) formation (Fig 5B, lanes 5 and 6). The lack of
Topo2cc formation in polyamide 1 treated samples as compared to linearized DNA and etopo-
side-treated samples is consistent with disruption of Topo2 binding.
Discussion
In this study, we evaluated the activity of an ARE targeted polyamide in VCaP human prostate
cancer cells. Polyamide 1 has been previously shown to exhibit antitumor activity in cell culture
and in xenografts of the androgen sensitive LNCaP cell line [19], but there are several impor-
tant genotypic differences between these two cell lines. First, VCaP cells possess an amplified
AR region, leading to higher levels of AR protein than LNCaP cells [30, 39, 40]. Additionally,
VCaP cells belong to a subtype of prostate cancer that possesses the TMPRSS2:ERG fusion,
resulting in the AR driven expression of ERG [23]. ERG, an oncogenic transcription factor, has
been reported to increase double stranded DNA break formation in PrEC cells, while
Fig 4. Genome wide expression analysis of VCaP cells treated with 10 μM polyamide 1 for 96 h. (A) Scatter plot of gene expression changes in VCaP
cells after polyamide treatment. (B) Connectivity map analysis of perturbagens that correlate with gene expression changes induced by polyamide 1. Bolded
compounds are topoisomerase inhibitors.
doi:10.1371/journal.pone.0143161.g004
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knockdown of ERG by siRNA in VCaP cells have been shown to decrease DNA breaks [41].
Studies have also shown that ERG overexpression increases cancer invasiveness and has been
correlated to increased metastasis in the clinic [25, 26].
In VCaP cell culture experiments, polyamide 1 exhibited antiproliferative activity and atten-
uated the DHT induced expression of select AR driven genes including TMPRSS2:ERG. Fur-
thermore, in this cell line with high genomic instability due to ERG overexpression, treatment
with polyamide 1 repressed the high level of DNA fragmentation found in the basal state,
which may be attributed to diminished ERG protein. In vivo, VCaP xenografts treated with
polyamide 1 exhibited reduced growth in a dosage dependent manner, demonstrating its
potential as an anticancer therapeutic.
To further examine the mechanism of action for polyamide 1, we conducted gene expres-
sion analysis of VCaP cells after exposure to polyamide 1 in the same time frame as the cyto-
toxic experiment. Connectivity map analysis of gene expression signatures from treated VCaP
cells indicated overlap with expression profiles of several topoisomerase inhibitors. In vitro
assays for inhibition of both Topo1 and Topo2 confirmed that polyamide 1 is able to attenuate
enzymatic activity of both enzymes. Similar results have been reported for other minor groove
binders [42–47]. Furthermore, the lack of topoisomerase 2 cleavage complex formation in the
inhibition assays suggests polyamide 1 functions by preventing protein-DNA interactions.
This mechanism is in contrast to most drugs that target topoisomerases, which poison the
enzymes. Drugs such as etoposide, doxorubicin, and camptothecin work by causing covalent
adducts, which results in genotoxicity [48].
In addition to inhibition of Topo1 and Topo2, polyamide 1 has been reported to antagonize
AR signaling, block RNA polymerase II elongation, and affect DNA replication by impeding
Fig 5. Inhibition of topoisomerase I and II by polyamide 1 in vitro. (A) Supercoiled DNA relaxation assay for topoisomerase I treated with increasing
concentrations of polyamide 1. Camptothecin (CPT) is used as a positive control. (B) Supercoiled DNA relaxation assay for topoisomerase IIα-p170
fragment. Etoposide (ETS) is used as a control. Rel, relaxed; OC, open circular; SC, supercoiled; Lin, linear; Rel. topoisomers, relaxed topoisomers; Prot. K,
proteinase K.
doi:10.1371/journal.pone.0143161.g005
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helicase processivity [19, 21, 49]. These effects may be related, as inhibition of Topo1 has been
shown to lead to RNA polymerase II and DNA polymerase stalling [50], and treatment of pros-
tate cancer cells with topoisomerase inhibitors has been shown to attenuate AR signaling [35,
36, 51, 52]. Taken together, these data suggest that by virtue of targeting DNA and DNA:pro-
tein interactions, polyamide 1may exhibit antiproliferative effects on cancer cells through
polypharmacological mechanisms without inducing genotoxic stress.
Supporting Information
S1 Fig. (A) Chemical structure of 1-FITC. (B) Nuclear localization of 1-FITC in VCaP cells
are 24 h and 48 h incubation.
(PNG)
S2 Fig. Mass spectrometry data for Py-Im polyamides used. All polyamides were character-
ized using high resolution MALDI-TOF. Because this method leads to cleavage of fluorescein,
FITC functionalized polyamides were also characterized by liquid chromatography coupled
mass spectrometry (LCMS) equipped with a low resolution ionization spectrometer.
(PNG)
S3 Fig. Primer sequences for qPCR analysis. Sequences for mRNA analysis without a listed
reference () were designed using qPrimerDepot (primerdepot.nci.nih.gov), and the single
amplification products verified by agarose gel electrophoresis against the 1.1 kN NEB ladder.
(PNG)
S4 Fig. Report of two-way ANOVA analysis from Prism software (GraphPad) for Comet
assays in VCaP cells.
(PNG)
S5 Fig. (A) Table of mRNA expression levels for AR-driven genes under DHT-induced con-
ditions in response to 10 μM polyamide 1. VCaP cells were plated at 31k/cm2, treated with
medium containing 0.1% DMSO (with or without polyamide) and charcoal-treated FBS
(CT-FBS) for 72 h followed by induction with 1 nM dihydrotestosterone (DHT) or vehicle
for an additional 24 h. —mRNA expression levels below threshold. (B) mRNA expression
data for polyamides at 1 and 10 μM concentration. VCaP cells plated at 31k/cm2 were
treated with medium containing 0.1% DMSO vehicle (with or without polyamide) for 72h.
mRNA levels were measured by qPCR, referenced to GUSB, and the polyamide effects com-
pared to vehicle treated samples. Data shown are average of the fold changes (treated/
untreated) for three or more biological replicates +/- standard error.
(PNG)
S6 Fig. Connectivity map analysis of perturbagens that correlate with gene expression
changes induced by polyamide 1 in LNCaP cells. Bolded compounds are topoisomerase
inhibitors.
(PNG)
S7 Fig. Effect of topoisomerase inhibitors on gene expression in VCaP cells. VCaP cells
were plated at 31k/cm2, incubated for 24 h, and then treated with medium containing 0.1%
DMSO (with or without camptothecin or etoposide) and DHT for 16 h. mRNA levels were
measured by qPCR, referenced to GUSB, and the effects compared to vehicle treated samples.
Data shown are the average fold changes (treated/untreated) for three biological replicates +/-
standard error.
(PNG)
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